Better Decisions,
Better Lives
We’re dedicated to empowering doctors and patients with the knowledge they need to understand how the body reacts to treatments like immunotherapy and radiation, making it possible to create more personalized cancer care plans.
CO-FOUNDER
Frank Slack, PhD
Dr. Slack is currently the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine at Beth Israel Deaconess Medical Center. His pioneering genetic research led to the discovery of let-7, one of the first microRNAs discovered, which he was able to show regulated cancer-causing genes. Dr. Slack is an internationally renowned researcher and lecturer on microRNAs, one of the fastest-growing and exciting areas of genetic research.
250+
PUBLICATIONS
84
H-INDEX
Scopus - Elsevier
30+
YEARS IN RESEARCH
CO-FOUNDER
Joanne Weidhaas, MD, PhD
Dr. Weidhaas’ residency at Memorial Sloan-Kettering Cancer Center shaped her career. There, she realized that a genetic predisposition was likely behind the cancer diagnoses in otherwise healthy patients and the varied responses and toxicities to treatment that they experienced. These insights led to her co-discovery of the KRAS-variant, an inherited genetic difference that enables more personalized treatment approaches. Inspired by this breakthrough, Dr. Weidhaas co-founded MiraDx, a company dedicated to advancing personalized medicine by applying this class of novel biomarkers to enable personalized assessment of response and toxicity profiles in cancer patients.
125+
PUBLICATIONS
38
H-INDEX
Scopus - Elsevier
25+
YEARS IN RESEARCH
20+
YEARS IN PRACTICE
Our Tests
In Research
PREVIOTOX
Helps physicians identify the risk of adverse events to immune checkpoint inhibitors.
Learn moreWhile late genitourinary toxicity following SBRT for prostate cancer is rare, when we do see it, those are the cases that stick with us as oncologists. We’ve long known that radiation dose doesn’t tell the whole story, and with this test, we have the ability to understand more about how a patient’s individual biology can influence their risk for side effects. Armed with this information, we can individualize and personalize our radiation treatment recommendations for our patients and reduce the risk of late toxicity.”
Luca F. Valle, MD, Radiation Oncologist
Assistant Professor in the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA
